NCT02706119

Insulin in Total Parenteral Nutrition

Subcutaneous Versus Intravenous Basal Insulin in Non-critical Hospitalized Diabetic Patients That Receive Total Parenteral Nutrition

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 163 (actual)
• Sponsor: Fundación Pública Andaluza Progreso y Salud · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Analyze the level of metabolic control achieved with a routine of regular insulin in the parenteral nutrition (PN) reservoir in addition to subcutaneous glargine insulin, versus only regular insulin in the PN reservoir.

Detailed description

A pattern of basal insulin (using subcutaneous insulin glargine and regulating the stock as prandial), plus regular subcutaneous insulin as rescue, applied to total parenteral nutrition (TPN) should be as effective (glycemic control, variability) and safe (hypoglycemia) as the usual (regular insulin inside the TPN reservoir and subcutaneous insulin as rescue) in patients with type 2 diabetes critics.

Conditions

• Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Subcutaneous glargine insulin	Glargine insuline is an insulin analogue which has a prolonged duration of action. Insulin glargine is obtained by recombinant DNA technology in Escherichia coli.
DRUG	Regular insulin added to TPN bag	Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.

Timeline

• Start date: 2016-07-01
• Primary completion: 2018-03-31
• Completion: 2018-04-04
• First posted: 2016-03-11
• Last updated: 2018-05-24

Locations

32 sites across 1 country: Spain